Is DHC a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Diversified Healthcare Trust (DHC) rests on Senior housing (SHOP) recovery: DHC's senior living operating portfolio is the main earnings lever, and it is recovering as occupancy and rates climb. Revenue (Q1 2026) is ~$366.5M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: DHC is a leveraged small-cap REIT and remains higher risk than large diversified peers. Whether DHC is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Diversified Healthcare Trust is a real estate investment trust that owns a roughly $6.2 billion portfolio of about 285 properties across 33 states and Washington, D.C. Its assets split into two main buckets: a senior housing operating portfolio (SHOP, roughly 23,900 senior living units) and medical office plus life science space (about 5.6 million square feet leased to roughly 250 tenants). DHC is externally managed by The RMR Group (Nasdaq: RMR), a commercial real estate asset manager with over $37 billion under management, so DHC has no employees of its own and pays management fees to RMR. The investment picture is a recovery and deleveraging story. DHC cut its common dividend to a token $0.01 per quarter during the pandemic-era downturn in senior housing and has been reshaping the portfolio through asset sales while occupancy and rates recover. First quarter 2026 revenue was about $366.5 million (down from ~$386.9 million a year earlier as it sells assets), and the company still runs a net loss, but consolidated NOI and normalized FFO are rising. Management guides to double-digit SHOP NOI growth for 2026 and, after repaying its 2026 zero coupon notes, has no debt maturing until 2028. The result is a leveraged, volatile small-cap where value depends on the senior housing rebound outrunning a still-heavy ~$2.4 billion debt load.
What's the case for buying DHC?
1. Senior housing (SHOP) recovery
DHC's senior living operating portfolio is the main earnings lever, and it is recovering as occupancy and rates climb. First quarter 2026 SHOP NOI rose to about $43.6 million, and management guides to roughly 26 to 33 percent SHOP NOI growth for full year 2026. This demographic tailwind (an aging U.S. population and limited new supply) is the core of the bull case.
2. Deleveraging and maturity runway
DHC carries roughly $2.42 billion of total debt, and reducing that burden is central to the story. It fully repaid its 2026 zero coupon senior secured notes in December 2025, freeing 45 collateral properties, and now has no debt maturing until 2028. That runway gives the recovery time to play out and lowers refinancing risk in the near term.
3. Portfolio repositioning and asset sales
Management has been selling medical office, life science, and other properties to raise cash and concentrate the portfolio. This shrinks reported revenue (down year over year) but is intended to strengthen the balance sheet and focus capital on the higher-growth SHOP segment. Execution on dispositions at reasonable prices is a key swing factor.
4. Stable medical office and life science base
The medical office and life science portfolio (about 5.6 million square feet across roughly 250 tenants) provides a steadier, lease-based cash flow stream that offsets the more operationally sensitive senior housing side. Management guides to broadly stable results here in 2026, giving the overall portfolio a more defensive counterweight.
What are the risks to DHC?
DHC is a leveraged small-cap REIT and remains higher risk than large diversified peers. It still posts net losses (a ~$43.3 million loss in the first quarter of 2026), carries roughly $2.4 billion of debt against a ~$2.2 billion equity market cap, and pays only a token $0.01 quarterly common dividend, so it is not an income vehicle. As an externally managed REIT, it pays fees to The RMR Group, which can create conflicts of interest that some investors dislike. The senior housing recovery could stall on labor costs, occupancy softness, or higher-for-longer interest rates, and asset sales could dilute future earnings if made at weak prices. The stock is volatile and sensitive to interest rate moves.
How is DHC valued? (as of July 2026)
Snapshot for DHC as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (Q1 2026): ~$366.5M
- Revenue (TTM): ~$1.45B
- Net loss (Q1 2026): ~$43.3M (-$0.18/sh)
- Normalized FFO (2026 guide): ~$125-140M ($0.52-0.58/sh)
- Market cap: ~$2.2B
- Total debt: ~$2.42B
DHC is a small-cap REIT best measured on FFO and NOI rather than net income, since large non-cash items (depreciation, impairments, gains on sales) swing reported earnings. On a price-to-normalized-FFO basis (~$0.52-0.58 for 2026 against a high-single-digit share price) it screens cheap versus larger healthcare REITs, reflecting its leverage and recovery risk. The near-zero common dividend means valuation rests on the balance sheet and NOI trajectory, not yield.
How do you decide if DHC is a buy?
Rather than asking whether DHC is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold DHC indirectly through an index or sector ETF before adding more.
For the full picture, see the DHC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about DHC against your real portfolio and see your actual exposure before deciding.
The bottom line on DHC
The bottom line: Diversified Healthcare Trust's story right now is Senior housing (SHOP) recovery, with revenue (q1 2026) at ~$366.5M. If you believe that narrative continues, the call is about sizing DHC sensibly and checking overlap with what you own; if you doubt it (the risk: dHC is a leveraged small-cap REIT and remains higher risk than large diversified peers.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
More on DHC
- DHC stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- DHC stock forecast (the drivers and risks shaping the outlook)
- Does DHC pay a dividend?
Build a basket around DHC with Walnut
Use Diversified Healthcare Trust as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is DHC a good stock to buy right now?
+
The case for Diversified Healthcare Trust right now is Senior housing (SHOP) recovery, with revenue (q1 2026) at ~$366.5M. If you believe that thesis holds, DHC is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is dHC is a leveraged small-cap REIT and remains higher risk than large diversified peers. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Diversified Healthcare Trust do?
+
Diversified Healthcare Trust is a real estate investment trust that owns a roughly $6.2 billion portfolio of about 285 properties across 33 states and Washington, D.C.
What are the main risks of DHC?
+
DHC is a leveraged small-cap REIT and remains higher risk than large diversified peers. It still posts net losses (a ~$43.3 million loss in the first quarter of 2026), carries roughly $2.4 billion of debt against a ~$2.2 billion equity market cap, and pays only a token $0.01 quarterly common dividend, so it is not an income vehicle. As an externally managed REIT, it pays fees to The RMR Group, which can create conflicts of interest that some investors dislike. The senior housing recovery could stall on labor costs, occupancy softness, or higher-for-longer interest rates, and asset sales could dilute future earnings if made at weak prices. The stock is volatile and sensitive to interest rate moves.
What does Diversified Healthcare Trust (DHC) do?
+
DHC is a real estate investment trust that owns roughly 285 healthcare properties across the U.S., split between senior living communities (its SHOP segment) and medical office plus life science buildings. It is externally managed by The RMR Group, so it owns and operates real estate rather than providing healthcare services directly.
Is DHC a good dividend stock?
+
DHC currently pays only a token common dividend of about $0.01 per quarter (a yield near 0.4 percent), after cutting it during the senior housing downturn. It is not a meaningful income vehicle today; its appeal is tied to a potential recovery in earnings and the balance sheet, not current yield.
How did DHC perform in its latest quarter?
+
In the first quarter of 2026 DHC reported revenue of about $366.5 million (down from ~$386.9 million a year earlier due to asset sales) and a net loss of about $43.3 million, or $0.18 per share. Consolidated NOI and normalized FFO both rose year over year, helped by senior housing gains and lower interest costs.
Who manages DHC and why does that matter?
+
DHC is externally managed by The RMR Group (Nasdaq: RMR), which handles buying, selling, financing, and operating its properties. External management means DHC has no employees and pays fees to RMR, an arrangement that can create conflicts of interest and is a factor some investors weigh when evaluating the stock.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell DHC; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.